drugset / Trial / NCT00739830
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare progression-free survival (PFS) of patients with advanced, recurrent or metastatic endometrial cancer who have received one, but not more than two, prior lines of chemotherapy either as adjuvant therapy or treatment for advanced disease, and then when treated with ridaforolimus or the investigators' choice of progestin or chemotherapy.
Timeline
- Start
- 2008-08
- Primary completion
- 2011-02
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Doxorubicin | Other / unclassified | — | — |
| Comparator | Megestrol Acetate | Other / unclassified | 40 mg | Oral |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Topotecan | Small molecule | — | — |
| Comparator | medroxyprogesterone acetate | Other / unclassified | 200 mg | Oral |
| Subject | ridaforolimus | Small molecule | 40 mg | Oral |